OST-tADC-FRα-H / OS Therapies - LARVOL DELTA

OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates (Businesswire) - "OS Therapies...announced the development and in vitro concept data for two novel ADC therapeutic candidates leveraging the Company’s proprietary SiLinker technology. The Company has completed target engagement tests for both therapeutic candidates and confirmed their therapeutic potential. These new constructs will target Breast, Lung and Gastric Cancer; and Ovarian, Fallopian Tube and Primary Peritoneal Cancer, respectively....The Company’s first tADC asset OST-tADC-FRα-H has achieved proof of concept in animal models of ovarian cancer....All while continuing to focus its internal resources on bringing to market the OST-HER2 off-the-shelf immunotherapy cancer vaccine platform for canines with osteosarcoma, and for humans with osteosarcoma and other HER2 positive cancers such as breast cancer and colorectal cancer."

Preclinical • Breast Cancer • Colorectal Cancer • Fallopian Tube Cancer • Gastric Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Lung Cancer • Oncology • Osteosarcoma • Ovarian Cancer • Peritoneal Cancer • Sarcoma • Solid Tumor